MASCT by Hengrui Yuanzheng Biotechnology for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval

MASCT is under clinical development by Hengrui Yuanzheng Biotechnology and currently in Phase I for Kidney Cancer (Renal Cell Cancer).

SII and Oxford University’s malaria vax launched in Côte d’Ivoire

SII has already produced 25 million doses and aims to further increase production to 100 million doses per year. Credit: Diana Polekhina on Unsplash. The

July 16, 2024

FDA proposes changes to key approval pathway for medical devices, five years after promising

Five years after promising to fix a flawed regulatory pathway widely used by medical device manufacturers, the Food and Drug Administration has issued new guidelines

September 12, 2023

Bristol Myers to buy cancer player Mirati for more than $4.8 billion

Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug Krazati, for $4.8 billion in cash in a deal that

October 9, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.